Professor Tim Warner
Director of Blizard Institute, Professor of Vascular Inflammation
Email: email@example.comTelephone: +44 20 7882 2333
Tim Warner graduated in pharmacology in 1986 from King’s College London. He then moved to the newly established William Harvey Research Institute to pursue his PhD studies under the supervision of Prof. Sir John Vane (Nobel Laureate, 1982) during which time he was awarded the Premier Prix Annuel de Recherche en Phlébologie. In 1989 he completed his PhD and went to pursue his post-doctoral studies with Ferid Murad (Nobel Laureate, 1998) at Northwestern University and Abbott Laboratories, Chicago, USA. He returned to the William Harvey Research Institute in 1992, being awarded a British Heart Foundation lectureship in 1995. He was promoted Reader in Pharmacology in 1999 and awarded a personal chair in Vascular Inflammation in 2000, at which time he was the recipient of the British Pharmacology Society’s Novartis Prize. Prof. Warner has been listed by the Institute for Scientific Information among the top 0.5% of cited pharmacologists. Before being appointed Director of the Blizard Institute he was Deputy Dean for Research in the School of Medicine and Dentistry and Deputy Director (Research & Innovation) of Queen Mary University of London's Life Science Initiative. Prof. Warner is a Fellow of the British Pharmacological Society, the American Heart Association, the Society of Biology and the Higher Education Academy. He is also a member of the British Society for Cardiovascular Research, International Society for Hypertension Research and the International Society on Thrombosis and Haemostasis. Prof. Warner is currently principal editor of the journal ‘Platelets’.
Topics for PhD supervision:
- Inflammation: Experimental Medicine & Pharmacology
- Cardiovascular: Experimental Medicine & Pharmacology
Prof. Warner’s main focus of current research is into the regulation of the function of blood platelets. Recent studies have focussed particularly upon the ways the functions of platelets change as they age within the circulation, and this work is now supported by programme grant funding from the British Heart Foundation. He has also conducted numerous studies into the roles of different enzyme pathways in the formation of vasoactive mediators such as prostaglandin I2, thromboxane A2 and nitric oxide in blood vessels and blood cells, and so to the control of platelet reactivity within the circulation and the mechanisms of actions of anti-platelet drugs. Much of this work has been conducted in collaboration with Prof. Jane Mitchell at Imperial College supported by funding from the Wellcome Trust and British Heart Foundation, and within Queen Mary by the European Union. Locally, research into platelet reactivity is being pursued in collaboration with clinical colleagues in the Trauma Department, Haematology Department and Cardiac Directorate of the Barts and The London NHS Trust, and NHS Blood and Transplant.
Kidney Transplantation in a Patient Lacking Cytosolic Phospholipase A2 Proves Renal Origins of Urinary PGI-M and TX-M. Mitchell JA, Knowles RB, Kirkby NS, Reed DM, Edin ML, White WE, Chan MV, Longhurst H, Yaqoob MM, Milne GL, Zeldin DC, Warner TD. Circ Res. 2018 Feb 16;122(4):555-559. doi: 10.1161/CIRCRESAHA.117.312144. Epub 2018 Jan 3.
Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. Armstrong PC, Hoefer T, Knowles RB, Tucker AT, Hayman MA, Ferreira PM, Chan MV, Warner TD. Arterioscler Thromb Vasc Biol. 2017 May;37(5):949-956. doi: 10.1161/ATVBAHA.116.308763. Epub 2017 Mar 9.
Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. Hoefer T, Armstrong PC, Finsterbusch M, Chan MV, Kirkby NS, Warner TD. Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2122-33. doi: 10.1161/ATVBAHA.115.306219. Epub 2015 Aug 13.
Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. Armstrong PC, Kirkby NS, Chan MV, Finsterbusch M, Hogg N, Nourshargh S, Warner TD. Blood. 2015 Sep 3;126(10):e11-8. doi: 10.1182/blood-2015-01-621656. Epub 2015 Jul 27.
Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. Lordkipanidzé M, Lowe GC, Kirkby NS, Chan MV, Lundberg MH, Morgan NV, Bem D, Nisar SP, Leo VC, Jones ML, Mundell SJ, Daly ME, Mumford AD, Warner TD, Watson SP; UK Genotyping and Phenotyping of Platelets Study Group. Blood. 2014 Feb 20;123(8):e11-22. doi: 10.1182/blood-2013-08-520387. Epub 2014 Jan 9.
- Dr Paul Amstrong
- Dr Melissa Chan
- Dr Marilena Crescente
- Dr Paul Vulliamy
- Ms Harriet Allen
- Ms Melissa Hayman
- Ms Laura Menke
- Ms Ivana Vojnovic